Answers are grounded in this paper and cite their sources.
These data suggest that Q4W is an effective dosing regimen for most patients who achieved stable disease control as shown by clear/almost clear skin and no itch to mild itch over 4 consecutive weeks on the initial regimen of tralokinumab Q2W.
No takes yet. Share an insight, caveat, or question.
Weidinger et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: